• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

TNF α and Reactive Oxygen Signaling in Vascular Smooth Muscle Cells in Hypertension and Atherosclerosis.
TNFα and Reactive Oxygen Signaling in Vascular Smooth Muscle Cells in Hypertension and Atherosclerosis. Am J Hypertens. 2020 Jun 05;: Authors: Lamb FS, Choi H, Miller MR, Stark RJ Abstract Hypertension and atherosclerosis, the predecessors of stroke and myocardial infarction, are chronic vascular inflammatory reactions. Tumor necrosis factor alpha (TNFα), the "master" pro-inflammatory cytokine, contributes to both the initiation and maintenance of vascular inflammation. TNFα induces reactive oxygen species (ROS) production which drives the redox reactions that constitute "ROS signaling". However, t...
Source: American Journal of Hypertension - June 4, 2020 Category: Cardiology Authors: Lamb FS, Choi H, Miller MR, Stark RJ Tags: Am J Hypertens Source Type: research

Reversible Cerebral Vasoconstriction Syndrome after Administering Etanercept during Puerperium
Our objective is to clarify relationship between reversible cerebral vasoconstriction syndrome and administrating etanercept during puerperium. Several lines of evidence have suggested tumor necrosis factor (TNF) as a mediator of vascular dysfunction associated with estrogen deficiency. A 32-year-old woman resumed etanercept (25 mg/week), a TNF inhibitor, which had been discontinued during pregnancy, because of the deterioration of rheumatoid arthritis. She was admitted to our hospital with upper right quadrant blindness and mild right hemiparesis accompanied by pulsating left occipital pain, which had appeared 4 hours aft...
Source: Journal of Stroke and Cerebrovascular Diseases - January 9, 2019 Category: Neurology Authors: Daisuke Hara, Saki Nukui, Takahiro Shimizu, Hisanao Akiyama, Yasuhiro Hasegawa Tags: Case Report Source Type: research

Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept.
CONCLUSIONS: RA patients with TCZ do not have a medium-term excess of CV risk in patients compared with ETN. PMID: 29303702 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - January 6, 2018 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Drugs used to treat joint and muscle disease
Publication date: Available online 19 February 2015 Source:Anaesthesia & Intensive Care Medicine Author(s): David G. Lambert Joint disease: Arthritis can be simply broken into osteoarthritis and rheumatoid arthritis (RA). Osteoarthritis is treated with symptomatic pain relief and surgery. RA is a chronic autoimmune disease that causes inflammation of joints (leading to their destruction), tissues around joints and other organ systems. Treatment (for pain) of RA in the first instance is with non-steroidal anti-inflammatory drugs, with second-line treatment using disease-modifying antirheumatic drugs (DMARDs). DMAR...
Source: Anaesthesia and intensive care medicine - February 24, 2015 Category: Anesthesiology Source Type: research

Rapidly Fatal Internal Carotid Artery Mycotic Aneurysm Rupture in a Rheumatoid Patient Taking a TNF-α Inhibitor: Case Report and Literature Review
Conclusions Although fungal mycotic aneurysms of the ICA are rare, their incidence may increase with the expanded use of immunosuppressive medications. Patients with rheumatoid arthritis who take potent immunosuppression regimens may be prime candidates for mycotic aneurysms because they often have two favoring conditions: atherosclerosis and immunosuppression. These ICA aneurysms carry a high mortality rate, so early diagnosis and aggressive therapy, potentially by endovascular trapping/vessel occlusion coupled with long-term antifungal therapy, is essential.[...]Georg Thieme Verlag KG Stuttgart · New YorkArticle in Th...
Source: Journal of Neurological Surgery Part A: Central European Neurosurgery - July 21, 2014 Category: Neurosurgery Authors: Bowers, Christian A.Saad, DanyClegg, Daniel O.Ng, PerryClayton, FredericHaydoura, SouhaSchmidt, Richard H. Tags: Case Report Source Type: research